randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 621 participants.
Also called NCT02900378
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 621 participants
- Sponsor
- Registry
-
NCT02900378 -
2016-003085-32
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Belgium, Bulgaria, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Iceland, Ireland, Latvia, Lithuania, Netherlands, Norway, Poland, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02900378. Randomized; triple masking; primary purpose treatment. Start 2016-12-20 (actual); primary completion 2018-04-11 (actual). Results posted on 2019-09-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
- Acronym
- OUTSTEP-HF
- Condition
- Chronic Heart Failure With Reduced Ejection Fraction
- Intervention (Drug)
- LCZ696 (Sacubitril/Valsartan)
- Intervention (Drug)
- Placebo of LCZ696 (Sacubitril/Valsartan)
- Intervention (Drug)
- Enalapril
- Intervention (Drug)
- Placebo of Enalapril
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct02900378- Content hash
7a5a7fca700541abdaca7fb5002f0cdc0011f16e81938565a01e567a8feaa455